Kadmon Holdings Inc

NASDAQ:KDMN  
3.77
-0.04 (-1.05%)
Products

Kadmon Holdings Says U.S. FDA Grants Full Approval Of REZUROCK(TM) (belumosudil) For The Treatment Of Patients With cGVHD

Published: 07/16/2021 18:48 GMT
Kadmon Holdings Inc (KDMN) - Kadmon Holdings Inc. - U.S. FDA Grants Full Approval of Rezurock(tm) (belumosudil) for the Treatment of Patients With Chronic Graft-versus-host Disease (cgvhd).
Kadmon Holdings Inc - FDA Approved Rezurock NDA Six Weeks Ahead of Prescription Drug User Fee Act Goal Date of August 30, 2021.
Kadmon Holdings - FDA Granted Breakthrough Therapy Designation & Priority Review for Rezurock & Reviewed NDA Under Rtor Pilot Program.
Kadmon Holdings Inc - Rezurock is Expected to Be Available in United States by Late August 2021.